Please assess the completion status of the following clinical trial:

Trial Title: ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion imaging study~Exclusion Criteria:~* Any condition precluding the safe administration of Adenoscan for a SPECT myocardial perfusion imaging study~* Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Regadenoson
- 2 (Type: ACTIVE_COMPARATOR): Adenoscan

Based on this trial design, predict the completion outcome and termination type (if applicable).